(+)-SJ733, a clinical candidate for malaria that acts through ATP4 to induce rapid host-mediated clearance of Plasmodium.
about
The malaria parasite cation ATPase PfATP4 and its role in the mechanism of action of a new arsenal of antimalarial drugsAntimalarial Drug Resistance: Literature Review and Activities and Findings of the ICEMR NetworkNext-generation antimicrobials: from chemical biology to first-in-class drugsOpen Source Drug Discovery: Highly Potent Antimalarial Compounds Derived from the Tres Cantos ArylpyrrolesA long-duration dihydroorotate dehydrogenase inhibitor (DSM265) for prevention and treatment of malariaOpen Source Drug Discovery with the Malaria Box Compound Collection for Neglected Diseases and BeyondUDP-galactose and acetyl-CoA transporters as Plasmodium multidrug resistance genesMuddled mechanisms: recent progress towards antimalarial target identificationAlternatives to currently used antimalarial drugs: in search of a magic bulletNew developments in anti-malarial target candidate and product profilesA New Set of Chemical Starting Points with Plasmodium falciparum Transmission-Blocking Potential for Antimalarial Drug DiscoveryEvidence of a Mild Mutator Phenotype in Cambodian Plasmodium falciparum Malaria ParasitesNa+ Influx Induced by New Antimalarials Causes Rapid Alterations in the Cholesterol Content and Morphology of Plasmodium falciparumComparative chemical genomics reveal that the spiroindolone antimalarial KAE609 (Cipargamin) is a P-type ATPase inhibitorA high-sensitivity HPLC assay for measuring intracellular Na(+) and K(+) and its application to Plasmodium falciparum infected erythrocytesThe Malaria Parasite's Lactate Transporter PfFNT Is the Target of Antiplasmodial Compounds Identified in Whole Cell Phenotypic ScreensA tetraoxane-based antimalarial drug candidate that overcomes PfK13-C580Y dependent artemisinin resistance.Bis-benzimidazole hits against Naegleria fowleri discovered with new high-throughput screens.Triaminopyrimidine is a fast-killing and long-acting antimalarial clinical candidate.Metabolomics-Based Screening of the Malaria Box Reveals both Novel and Established Mechanisms of Action.MinorityReport, software for generalized analysis of causal genetic variantsA Basis for Rapid Clearance of Circulating Ring-Stage Malaria Parasites by the Spiroindolone KAE609.Plasmid-free CRISPR/Cas9 genome editing in Plasmodium falciparum confirms mutations conferring resistance to the dihydroisoquinolone clinical candidate SJ733.High-Throughput Assay and Discovery of Small Molecules that Interrupt Malaria Transmission.Maduramicin Rapidly Eliminates Malaria Parasites and Potentiates the Gametocytocidal Activity of the Pyrazoleamide PA21A050.A broad analysis of resistance development in the malaria parasiteMetabolomic Profiling of the Malaria Box Reveals Antimalarial Target Pathways.SC83288 is a clinical development candidate for the treatment of severe malaria.Phylogenetic profiles of all membrane transport proteins of the malaria parasite highlight new drug targetsCeramide in the regulation of eryptosis, the suicidal erythrocyte death.Plasmodium falciparum in vitro continuous culture conditions: A comparison of parasite susceptibility and tolerance to anti-malarial drugs throughout the asexual intra-erythrocytic life cycle.Screening the Medicines for Malaria Venture Pathogen Box across Multiple Pathogens Reclassifies Starting Points for Open-Source Drug Discovery.A validated bioluminescence-based assay for the rapid determination of the initial rate of kill for discovery antimalarials.Whole-Genome Sequencing to Evaluate the Resistance Landscape Following Antimalarial Treatment Failure With Fosmidomycin-Clindamycin.Identification of Plasmodium falciparum specific translation inhibitors from the MMV Malaria Box using a high throughput in vitro translation screenA Quinoline Carboxamide Antimalarial Drug Candidate Uniquely Targets Plasmodia at Three Stages of the Parasite Life Cycle.Suicidal death of erythrocytes in cancer and its chemotherapy: A potential target in the treatment of tumor-associated anemia.A potent series targeting the malarial cGMP-dependent protein kinase clears infection and blocks transmission.Antimalarial drug resistance: linking Plasmodium falciparum parasite biology to the clinic.Reduced deformability of parasitized red blood cells as a biomarker for anti-malarial drug efficacy.
P2860
Q26781634-978720CA-7529-4106-8093-198B360FFA46Q26799713-ED9CE343-870A-472B-9AAD-189A00BF01E8Q26799749-468AA85B-6F7D-4730-A17D-5284C249E4AFQ26883657-B119E9DA-2C16-41CB-8AB7-594D8978F7D8Q27644391-1590AFDC-1A6A-4E4E-AD89-E1B9E88BC0ADQ27826351-B179134C-2C62-4FA8-92E2-B55B19C34591Q27861953-5809212D-4C92-4794-9CAF-7975038D72B6Q28066421-B4938176-1F8E-4011-9DBC-D6EDE8B5ED3AQ28070398-5AEEFB5E-F85F-4C7C-81E2-B697E2ACE352Q28468598-CEBA34EE-0B76-401C-A323-DE1EA067EDBCQ28547546-143575E9-40E0-47CA-B674-E86E6655812CQ28551519-6ABD7555-1E8D-4A72-A3F7-9950E2F6847AQ28552457-3D827B93-FE25-4C80-84F4-25BD64E8C364Q28830547-1E6657F0-7A23-413B-ACA9-611F039EBC78Q28831140-C8323C8E-1A99-4F61-A6E9-58C80E74B095Q30042965-8064DE94-1E2D-4D06-A53C-71052A231712Q33761137-E591886B-E96F-4050-A87E-7A63F2B53661Q35169050-BC6E59B1-357F-4492-9047-E10E6AF176C1Q35311620-EDE79DEC-403B-4E4D-9A2F-FFF589749B82Q36116227-4AB10905-71AA-4EC6-B647-AACE31884CB7Q36288859-96201F4F-8B7F-46CA-8DE6-EF8A334E802EQ36365291-E558CCBF-4FFD-402E-8D4F-4B95B41774D5Q36380610-5869D758-238B-4C79-8EE9-FB081534B16CQ36492518-5C2DAC5E-8D68-42B1-8A56-1E90005E8DFAQ36644774-D58773ED-F890-4193-A0F3-5D77F1B3503BQ37017711-BD1947E8-8E44-4DCF-B77A-26A00EA845DEQ37358648-0FC02BC9-2241-490D-8EEF-6156FA0E9BBCQ37622611-BD718C76-6B6F-4201-BA6C-4B19FD346C1AQ37698115-3D7C96DD-FC77-4E2D-BE36-1978591FC25FQ38338337-11367A28-F80F-40E1-906C-CD43276ED350Q38664678-37058958-5E06-4D9C-A1A0-6CF4C33D0219Q38695331-33447F9F-6051-4D2E-A1E4-4D4D4396C2C7Q38780035-D520C7D5-430D-471A-A696-EB7A27C45F8EQ38839163-EE623C7A-DE33-48EE-A680-D03BF5C89EBBQ38893778-ACD0BD3E-CA5C-4A35-875A-D895585346D0Q39314820-FED3CDE8-D5FC-4951-AF78-6CB02BFA6C09Q39329194-FF8426E0-9E52-4B8D-BDCC-1632D8C40681Q40065688-1CEF007A-6521-4255-8250-E01702439801Q40106428-41FED1DE-C97B-4614-B712-DB50FA7E5C64Q40928786-7A0EC562-785C-4EFB-8215-85F4AE588126
P2860
(+)-SJ733, a clinical candidate for malaria that acts through ATP4 to induce rapid host-mediated clearance of Plasmodium.
description
2014 nî lūn-bûn
@nan
2014 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
(+)-SJ733, a clinical candidat ...... iated clearance of Plasmodium.
@ast
(+)-SJ733, a clinical candidat ...... iated clearance of Plasmodium.
@en
type
label
(+)-SJ733, a clinical candidat ...... iated clearance of Plasmodium.
@ast
(+)-SJ733, a clinical candidat ...... iated clearance of Plasmodium.
@en
prefLabel
(+)-SJ733, a clinical candidat ...... iated clearance of Plasmodium.
@ast
(+)-SJ733, a clinical candidat ...... iated clearance of Plasmodium.
@en
P2093
P2860
P50
P356
P1476
(+)-SJ733, a clinical candidat ...... diated clearance of Plasmodium
@en
P2093
Aaron N Endsley
Amy Matheny
Ane Rodríguez-Alejandre
Angela K Carrillo
Daniel Ebert
David M Floyd
David M Shackleford
David Waterson
Fangyi Zhu
Francisco-Javier Gamo
P2860
P304
P356
10.1073/PNAS.1414221111
P407
P50
P577
2014-12-01T00:00:00Z